首页 | 本学科首页   官方微博 | 高级检索  
     


Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response
Authors:Perttu Koskenvesa  Anna Kreutzman  Peter Rohon  Markus Pihlman  Emmi Vakkila  Anu Räsänen  Mirja Vapaatalo  Kari Remes  Tuija Lundán  Henrik Hjorth‐Hansen  Jukka Vakkila  Bengt Simonsson  Kimmo Porkka
Affiliation:1. Hematology Research Unit Helsinki, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, , Helsinki, Finland;2. Department of Hemato‐Oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, , Olomouc, Czech Republic;3. Kymenlaakso Central Hospital, , Kotka, Finland;4. Department of Medicine, Helsinki University central Hospital, , Helsinki, Finland;5. Turku University Central Hospital, , Turku, Finland;6. TYKSLAB, Turku University Central Hospital, , Turku, Finland;7. Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology (NTNU), , Trondheim, Norway;8. Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), , Trondheim, Norway;9. Uppsala University Hospital, , Uppsala, Sweden
Abstract:
Keywords:chronic myeloid leukemia  interferon  tyrosine kinase inhibitor  therapy discontinuation  immune system
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号